Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

September 28, 2010

Oncolytics Biotech Inc. Announces Issuance of Key U.S. Patent

September 27, 2010

Media Advisory – Oncolytics Biotech(R) Inc. to Present at JMP Securities Healthcare Conference

September 9, 2010

Media Advisory – Oncolytics Biotech(R) Inc. to Present at Rodman & Renshaw Annual Global Investment Conference

September 2, 2010

Oncolytics Biotech(R) Inc. Announces Randomized Phase II Ovarian Cancer Study to be Conducted by the Gynecologic Oncology Group and Sponsored by the National Cancer Institute

August 5, 2010

Media Advisory – Oncolytics Biotech(R) Inc. to Present at 30th Annual Canaccord Genuity Growth Conference

July 29, 2010

Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results

July 19, 2010

Oncolytics Biotech(R) Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN(R) in Head and Neck Cancers

June 17, 2010

Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent

June 7, 2010

Oncolytics Biotech(R) Inc. Collaborators Present Positive Updated U.K. Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the ASCO Annual Meeting

June 4, 2010

Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting

Page 52 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.